Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 428

1.

Safety and Varicella Outcomes in In Utero-Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program.

Duchon JM, Levin MJ, Gershon AA.

J Pediatric Infect Dis Soc. 2019 Nov 27. pii: piz070. doi: 10.1093/jpids/piz070. [Epub ahead of print]

PMID:
31774916
2.

Recurrent herpes zoster in the Shingles Prevention Study: Are second episodes caused by the same varicella-zoster virus strain?

Harbecke R, Jensen NJ, Depledge DP, Johnson GR, Ashbaugh ME, Schmid DS, Breuer J, Levin MJ, Oxman MN.

Vaccine. 2019 Oct 31. pii: S0264-410X(19)31411-2. doi: 10.1016/j.vaccine.2019.10.038. [Epub ahead of print]

3.

Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine.

Levin MJ, Weinberg A.

Clin Infect Dis. 2019 Oct 16. pii: ciz770. doi: 10.1093/cid/ciz770. [Epub ahead of print]

PMID:
31618437
4.

Archaeological assessment reveals Earth's early transformation through land use.

Stephens L, Fuller D, Boivin N, Rick T, Gauthier N, Kay A, Marwick B, Armstrong CG, Barton CM, Denham T, Douglass K, Driver J, Janz L, Roberts P, Rogers JD, Thakar H, Altaweel M, Johnson AL, Sampietro Vattuone MM, Aldenderfer M, Archila S, Artioli G, Bale MT, Beach T, Borrell F, Braje T, Buckland PI, Jiménez Cano NG, Capriles JM, Diez Castillo A, Çilingiroğlu Ç, Negus Cleary M, Conolly J, Coutros PR, Covey RA, Cremaschi M, Crowther A, Der L, di Lernia S, Doershuk JF, Doolittle WE, Edwards KJ, Erlandson JM, Evans D, Fairbairn A, Faulkner P, Feinman G, Fernandes R, Fitzpatrick SM, Fyfe R, Garcea E, Goldstein S, Goodman RC, Dalpoim Guedes J, Herrmann J, Hiscock P, Hommel P, Horsburgh KA, Hritz C, Ives JW, Junno A, Kahn JG, Kaufman B, Kearns C, Kidder TR, Lanoë F, Lawrence D, Lee GA, Levin MJ, Lindskoug HB, López-Sáez JA, Macrae S, Marchant R, Marston JM, McClure S, McCoy MD, Miller AV, Morrison M, Motuzaite Matuzeviciute G, Müller J, Nayak A, Noerwidi S, Peres TM, Peterson CE, Proctor L, Randall AR, Renette S, Robbins Schug G, Ryzewski K, Saini R, Scheinsohn V, Schmidt P, Sebillaud P, Seitsonen O, Simpson IA, Sołtysiak A, Speakman RJ, Spengler RN, Steffen ML, Storozum MJ, Strickland KM, Thompson J, Thurston TL, Ulm S, Ustunkaya MC, Welker MH, West C, Williams PR, Wright DK, Wright N, Zahir M, Zerboni A, Beaudoin E, Munevar Garcia S, Powell J, Thornton A, Kaplan JO, Gaillard MJ, Klein Goldewijk K, Ellis E.

Science. 2019 Aug 30;365(6456):897-902. doi: 10.1126/science.aax1192.

PMID:
31467217
6.

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.

Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Hervé C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL.

Hum Vaccin Immunother. 2019 Jun 28:1-8. doi: 10.1080/21645515.2019.1627818. [Epub ahead of print]

PMID:
31216205
7.

The origins of specialized pottery and diverse alcohol fermentation techniques in Early Neolithic China.

Liu L, Wang J, Levin MJ, Sinnott-Armstrong N, Zhao H, Zhao Y, Shao J, Di N, Zhang T.

Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12767-12774. doi: 10.1073/pnas.1902668116. Epub 2019 Jun 3.

8.

Evaluation of two frailty indices, with practical application in a vaccine clinical trial.

Curran D, Andrew MK, Levin MJ, Turriani E, Matthews S, Fogarty C, Klein NP, Grupping K, Oostvogels L, Schmader KE.

Hum Vaccin Immunother. 2019 Jun 21:1-9. doi: 10.1080/21645515.2019.1622974. [Epub ahead of print]

PMID:
31157595
9.

The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.

Weinberg A, Pang L, Johnson MJ, Caldas Y, Cho A, Tovar-Salazar A, Canniff J, Schmader KE, Popmihajlov Z, Levin MJ.

J Virol. 2019 Jul 17;93(15). pii: e00305-19. doi: 10.1128/JVI.00305-19. Print 2019 Aug 1.

PMID:
31092579
10.

Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults.

Weinberg A, Lambert SL, Canniff J, Yu L, Lang N, Esser MT, Falloon J, Levin MJ.

Hum Vaccin Immunother. 2019;15(10):2466-2474. doi: 10.1080/21645515.2019.1589282. Epub 2019 Jun 3.

PMID:
30852939
11.

Costs of herpes zoster complications in older adults: A cohort study of US claims database.

Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ.

Vaccine. 2019 Feb 21;37(9):1235-1244. doi: 10.1016/j.vaccine.2018.11.079. Epub 2019 Jan 23.

12.

Immune responses to zoster vaccines.

Levin MJ, Weinberg A.

Hum Vaccin Immunother. 2019;15(4):772-777. doi: 10.1080/21645515.2018.1560918. Epub 2019 Jan 24.

PMID:
30676834
13.

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.

Schmader KE, Levin MJ, Grupping K, Matthews S, Butuk D, Chen M, Idrissi ME, Fissette LA, Fogarty C, Hartley P, Klein NP, Nevarez M, Uusinarkaus K, Oostvogels L, Curran D.

J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1217-1224. doi: 10.1093/gerona/gly218.

14.

Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals.

Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ.

Vaccine. 2018 Oct 29;36(45):6810-6818. doi: 10.1016/j.vaccine.2018.08.080. Epub 2018 Sep 22.

15.

Comparative Immune Responses to Licensed Herpes Zoster Vaccines.

Weinberg A, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Levin MJ.

J Infect Dis. 2018 Sep 22;218(suppl_2):S81-S87. doi: 10.1093/infdis/jiy383.

PMID:
30247596
16.

Herpes Zoster Vaccines.

Cunningham AL, Levin MJ.

J Infect Dis. 2018 Sep 22;218(suppl_2):S127-S133. doi: 10.1093/infdis/jiy382. Review.

PMID:
30247592
17.

Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study.

Hawkins KL, Gordon KS, Levin MJ, Weinberg A, Battaglia C, Rodriguez-Barradas MC, Brown ST, Rimland D, Justice A, Tate J, Erlandson KM; VACS Project Team.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):527-533. doi: 10.1097/QAI.0000000000001846.

18.

Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine.

Weinberg A, Popmihajlov Z, Schmader KE, Johnson MJ, Caldas Y, Salazar AT, Canniff J, McCarson BJ, Martin J, Pang L, Levin MJ.

J Infect Dis. 2019 Jan 7;219(2):335-338. doi: 10.1093/infdis/jiy514.

PMID:
30165651
19.

A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.

Reisinger KS, Richardson E, Malacaman EA, Levin MJ, Gardner JL, Wang W, Stek JE, Kuter B.

Vaccine. 2019 Sep 10;37(38):5788-5795. doi: 10.1016/j.vaccine.2018.01.089. Epub 2018 Aug 23.

PMID:
30146405
20.

Varicella-zoster virus inhibits autophagosome-lysosome fusion and the degradation stage of mTOR-mediated autophagic flux.

Graybill C, Morgan MJ, Levin MJ, Lee KS.

Virology. 2018 Sep;522:220-227. doi: 10.1016/j.virol.2018.07.018. Epub 2018 Jul 24.

21.

Th1 memory differentiates recombinant from live herpes zoster vaccines.

Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A.

J Clin Invest. 2018 Oct 1;128(10):4429-4440. doi: 10.1172/JCI121484. Epub 2018 Jul 19.

22.

Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1-Infected Infants.

Koay WLA, Lindsey JC, Uprety P, Bwakura-Dangarembizi M, Weinberg A, Levin MJ, Persaud D.

J Infect Dis. 2018 Aug 24;218(7):1085-1089. doi: 10.1093/infdis/jiy271.

23.

Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV.

Erlandson KM, Streifel A, Novin AR, Hawkins KL, Foster C, Langness J, Bessesen M, Falutz J, Moanna A, Looney D, Johns ST, Nguyen JB, Oxman MN, Levin MJ.

AIDS Res Hum Retroviruses. 2018 Jul;34(7):603-606. doi: 10.1089/AID.2017.0315. Epub 2018 May 21.

24.

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.

Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ; ZOE-50/70 Study Group.

J Infect Dis. 2018 May 5;217(11):1750-1760. doi: 10.1093/infdis/jiy095.

25.

Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.

Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC; ZOE-50/70 Study Group.

Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17.

26.

Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.

Weinberg A, Huang S, Moscicki AB, Saah A, Levin MJ; IMPAACT P1085 Protocol Team.

AIDS. 2018 Apr 24;32(7):851-860. doi: 10.1097/QAD.0000000000001773.

27.

Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.

Levin MJ, Cai GY, Lee KS, Rouphael NG, Mehta AK, Canniff J, Mulligan MJ, Weinberg A.

J Infect Dis. 2018 Mar 13;217(7):1055-1059. doi: 10.1093/infdis/jix653.

28.

B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine.

Weinberg A, Lindsey J, Bosch R, Persaud D, Sato P, Ogwu A, Asmelash A, Bwakura-Dangarambezi M, Chi BH, Canniff J, Lockman S, Gaseitsiwe S, Moyo S, Smith CE, Moraka NO, Levin MJ; P1072 and Tshipidi Study Teams.

Front Immunol. 2018 Jan 19;8:2002. doi: 10.3389/fimmu.2017.02002. eCollection 2017.

29.

Studies with herpes zoster vaccines in immune compromised patients.

Levin MJ, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw KL, Willis E, Curtis JR.

Expert Rev Vaccines. 2017 Dec;16(12):1217-1230. doi: 10.1080/14760584.2017.1395703. Epub 2017 Nov 7. Review.

PMID:
29053937
30.

An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.

Falloon J, Yu J, Esser MT, Villafana T, Yu L, Dubovsky F, Takas T, Levin MJ, Falsey AR.

J Infect Dis. 2017 Dec 12;216(11):1362-1370. doi: 10.1093/infdis/jix503.

31.

Cytokines Produced in Response to Varicella-Zoster Virus Infection of ARPE-19 Cells Stimulate Lymphocyte Chemotaxis.

Graybill C, Claypool DJ, Brinton JT, Levin MJ, Lee KS.

J Infect Dis. 2017 Nov 15;216(8):1038-1047. doi: 10.1093/infdis/jix426.

PMID:
28968855
32.

Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.

Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E, Popmihajlov Z.

Vaccine. 2018 Jan 2;36(1):179-185. doi: 10.1016/j.vaccine.2017.08.029. Epub 2017 Aug 19.

33.

Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.

Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker JA, Levin MJ.

J Immunol. 2017 Jul 15;199(2):604-612. doi: 10.4049/jimmunol.1700290. Epub 2017 Jun 12.

34.

Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses.

Uprety P, Lindsey JC, Levin MJ, Rainwater-Lovett K, Ziemniak C, Bwakura-Dangarembizix M, Kaplan SS, Nelson M, Zadzilka A, Weinberg A, Persaud D.

J Infect Dis. 2017 Mar 15;215(6):928-932. doi: 10.1093/infdis/jix060.

35.

Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.

Levin MJ, Huang S, Moscicki AB, Song LY, Read JS, Meyer WA, Saah AJ, Richardson K, Weinberg A; IMPAACT P1085 Protocol Team.

Vaccine. 2017 Mar 23;35(13):1712-1720. doi: 10.1016/j.vaccine.2017.02.021. Epub 2017 Feb 24.

36.

Shedding Light on Shingles: The Power of Prevention.

Herman L, Levin MJ, Rehm S.

Am J Med. 2016 Oct;129(10):1137. doi: 10.1016/j.amjmed.2016.08.008.

PMID:
27671850
37.

Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.

Levin MJ, Lindsey JC, Kaplan SS, Schimana W, Lawrence J, McNeal MM, Bwakura-Dangarembizi M, Ogwu A, Mpabalwani EM, Sato P, Siberry G, Nelson M, Hille D, Weinberg GA, Weinberg A.

AIDS. 2017 Jan 2;31(1):49-59.

38.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group.

N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.

39.

Cost of Herpes Zoster in Patients With Selected Immune-Compromised Conditions in the United States.

Li Q, Chen SY, Burstin SJ, Levin MJ, Suaya JA.

Open Forum Infect Dis. 2016 Mar 24;3(2):ofw067. doi: 10.1093/ofid/ofw067. eCollection 2016 Apr.

40.

Incidence and consequences of varicella in children treated for cancer in Guatemala.

Brown AEC, Asturias EJ, Melgar M, Antillon-Klussmann FA, Mettler P, Levin MJ.

World J Pediatr. 2016 Aug;12(3):320-326. doi: 10.1007/s12519-016-0025-y. Epub 2016 Jun 29.

PMID:
27351567
41.

Herpes Simplex Virus and Varicella-Zoster Virus.

Levin MJ, Weinberg A, Schmid DS.

Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.DMIH2-0017-2015. Review.

PMID:
27337486
42.

Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina.

Niborski LL, Grippo V, Lafón SO, Levitus G, García-Bournissen F, Ramirez JC, Burgos JM, Bisio M, Juiz NA, Ayala V, Coppede M, Herrera V, López C, Contreras A, Gómez KA, Elean JC, Mujica HD, Schijman AG, Levin MJ, Longhi SA.

Mem Inst Oswaldo Cruz. 2016 May 24;111(6):365-71. doi: 10.1590/0074-02760160006.

43.

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir.

Smith C, Weinberg A, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ.

Infect Dis Obstet Gynecol. 2016;2016:9848041. doi: 10.1155/2016/9848041. Epub 2016 Apr 4.

44.

Regulatory T Cells in Infections: Getting It Just Right.

Levin MJ, Weinberg A.

J Infect Dis. 2016 Jul 1;214(1):4-5. doi: 10.1093/infdis/jiw092. Epub 2016 Apr 25. No abstract available.

PMID:
27117510
45.

Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.

Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, Weinberg A, Canniff J, Levin MJ.

Lancet Infect Dis. 2016 Aug;16(8):915-22. doi: 10.1016/S1473-3099(16)00133-X. Epub 2016 Apr 6.

PMID:
27061887
46.

Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.

Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L; VIVIANE Study Group.

Int J Cancer. 2016 May 15;138(10):2428-38. doi: 10.1002/ijc.29971.

47.

Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.

Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A.

J Infect Dis. 2016 Jan 1;213(1):14-22. doi: 10.1093/infdis/jiv480. Epub 2015 Oct 9.

PMID:
26452397
48.

Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women.

Weinberg A, Muresan P, Richardson K, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ; P1086 Study Team.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1170-7. doi: 10.1089/aid.2015.0151. Epub 2015 Aug 31.

49.

Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy.

Mirani G, Williams PL, Chernoff M, Abzug MJ, Levin MJ, Seage GR 3rd, Oleske JM, Purswani MU, Hazra R, Traite S, Zimmer B, Van Dyke RB; IMPAACT P1074 Study Team.

Clin Infect Dis. 2015 Dec 15;61(12):1850-61. doi: 10.1093/cid/civ687. Epub 2015 Aug 12.

50.

Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review.

Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ, Weinberg A.

PLoS One. 2015 May 22;10(5):e0127062. doi: 10.1371/journal.pone.0127062. eCollection 2015.

Supplemental Content

Loading ...
Support Center